MedTrace Logo

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

NCT00437359 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2012-03-30

No results posted yet for this study

Summary

To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Toremifene citrate

Toremifene citrate: 40-mg tablets by mouth once daily.

DRUG

Anastrozole

Anastrozole: 1-mg tablets by mouth once daily.

Sponsors & Collaborators

  • Japan Breast Cancer Research Network

    lead OTHER

Principal Investigators

  • Satoru Iwase, MD · Department of Palliative Medicine, The University of Tokyo Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2017-05-31
Completion
2020-05-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00437359 on ClinicalTrials.gov